Nucpaedia
Nucpaedia
Short read · Musculoskeletal

Bone Radiopharmaceuticals Compared

Musculoskeletal · 3 min read

Diagnostic bone agents and bone-targeted therapies, side by side

Most skeletal radiopharmaceuticals either bind the mineral surface through a phosphate or phosphonate group, or behave like calcium. That one distinction explains why the diagnostic diphosphonates look alike, why pyrophosphate left routine bone imaging, and why the therapy agents differ mainly in their physics.

Diagnostic agents

AgentUptakePhysical half-lifeMain useDistinction
⁹⁹ᵐTc-MDPAdsorbs to hydroxyapatite in proportion to blood flow and osteoblastic activity6 hRoutine bone scan; SPECT/CTThe standard; not recommended for cardiac ATTR
⁹⁹ᵐTc-HDP (HMDP)As MDP6 hBone scan; cardiac ATTRRecommended ATTR tracer
⁹⁹ᵐTc-DPDAs MDP6 hBone scan; cardiac ATTRRecommended ATTR tracer
⁹⁹ᵐTc-PYPBone-avid pyrophosphate; cardiac uptake mechanism unsettled6 hCardiac ATTRSlower clearance; no longer a routine skeletal agent
¹⁸F-NaFFluoride exchanges with hydroxyl groups in hydroxyapatite110 minBone PET/CTHigher bone uptake, faster clearance, higher resolution; axial imaging from 30–45 min; needs PET

Why diphosphonates replaced pyrophosphate

  • Pyrophosphate has a P–O–P bridge, which alkaline phosphatase hydrolyses.
  • Diphosphonates replace the oxygen with carbon. The P–C–P bridge resists hydrolysis in vivo.
  • In the original comparison, ⁹⁹ᵐTc-MDP cleared from blood faster than pyrophosphate and gave good images from 2 hours; pyrophosphate needed about 4 hours.
  • HDP and DPD share the P–C–P bridge, so the bond gives MDP no edge over them. In a head-to-head study they offered no clinical advantage over MDP for metastases. MDP is common because it is established and widely available.
Pearl

For cardiac ATTR imaging use DPD, HDP or PYP. MDP is not recommended.

Bone-targeted therapy

AgentTargetingEmission; half-lifeMain roleAdvantage or drawback
⁸⁹Sr-chlorideCalcium analogue; osteoblastic sitesβ⁻; 50.5 dPainful osteoblastic metastasesLong-acting; marrow nadir at 12–16 weeks
¹⁵³Sm-EDTMPPhosphonate binds bone mineralβ⁻ + 103 keV γ; 46.3 hPainful osteoblastic metastasesγ allows post-therapy imaging; nadir at 3–5 weeks
¹⁸⁶Re-HEDPHEDP phosphonateβ⁻ + 137 keV γ; 3.7 dMetastatic bone painImageable; limited availability
¹⁸⁸Re-HEDPHEDP phosphonateβ⁻ + 155 keV γ; 17 hMetastatic bone painOn demand from a ¹⁸⁸W/¹⁸⁸Re generator; faster dose delivery
²²³Ra-dichlorideCalcium mimetic; binds hydroxyapatite at high turnoverα; 11.4 dCastration-resistant prostate cancer with symptomatic bone metastases, no known visceral metastasesRange under 100 µm; survival benefit
³²P-sodium phosphatePhosphate incorporated into hydroxyapatiteβ⁻; 14.3 dOlder bone-pain treatmentMyelosuppression limits use

Using the therapies

  • β⁻ emitters palliate pain: about 70% respond to a single treatment, with onset over days to 4 weeks. None has shown a survival benefit.
  • Before a β⁻ emitter, a bone scan within 8 weeks must show osteoblastic uptake at the painful sites. A superscan is a contraindication.
  • In ALSYMPCA, ²²³Ra improved median overall survival from 11.3 to 14.9 months (hazard ratio 0.70).
  • The EU label now restricts ²²³Ra to progression after at least two prior systemic lines, or no other option, and forbids combination with abiraterone and prednisone/prednisolone (more fractures, trend to higher mortality).
Pearl

Sr and Ra mimic calcium. Tc, Sm and Re ride phosphonate carriers; ³²P is phosphate itself. FDG and PSMA target tumour biology, not bone mineral.

Take home
  • The P–C–P bond explains why diphosphonates replaced pyrophosphate; between MDP, HDP and DPD there is no decisive diagnostic advantage.
  • For cardiac ATTR use DPD, HDP or PYP, not MDP.
  • β⁻ emitters palliate bone pain; only ²²³Ra prolongs survival, in castration-resistant prostate cancer with symptomatic bone metastases and no visceral disease.
Sources
  1. Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016;43(9):1723-38.
  2. Segall G, Delbeke D, Stabin MG, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51(11):1813-20.
  3. Subramanian G, McAfee JG, Blair RJ, et al. Technetium-99m-methylene diphosphonate: a superior agent for skeletal imaging. Comparison with other technetium complexes. J Nucl Med. 1975;16(8):744-55.
  4. Pauwels EK, Blom J, Camps JA, et al. A comparison between the diagnostic efficacy of 99mTc-MDP, 99mTc-DPD and 99mTc-HDP for the detection of bone metastases. Eur J Nucl Med. 1983;8(3):118-22.
  5. Cook GJR. Imaging with radiolabelled bisphosphonates. Bone. 2020;137:115372.
  6. Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2-19.
  7. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075.
  8. Mori A, Saito Y, Nakamura K, et al. Microcalcification and 99mTc-pyrophosphate uptake without increased bone metabolism in cardiac tissue from patients with transthyretin cardiac amyloidosis. Int J Mol Sci. 2023;24(3):1921.
  9. Handkiewicz-Junak D, Poeppel TD, Bodei L, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging. 2018;45(5):846-59.
  10. Poeppel TD, Handkiewicz-Junak D, Andreeff M, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(5):824-45.
  11. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-23.
  12. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45(8):1358-65.
  13. Lange R, Ter Heine R, Knapp FF, et al. Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases. Bone. 2016;91:159-79.
  14. European Medicines Agency. Xofigo (radium-223 dichloride): summary of product characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo
  15. International Atomic Energy Agency, Nuclear Data Section. Live Chart of Nuclides (ENSDF evaluated half-lives and gamma lines). Available from: https://www-nds.iaea.org/relnsd/vcharthtml/VChartHTML.html
← BackShort reads

Spotted an error or something out of date? Report an error